Cas:129705-30-2 (3S,6S)-2,7-dimethyloctane-3,6-diol manufacturer & supplier

Chemical Name:(3S,6S)-2,7-dimethyloctane-3,6-diol

CAS.NO:129705-30-2

Synonyms:MFCD01631077

Molecular Formula:C₁₀H₂₂O₂

Molecular Weight:174.28000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:252.2ºC at 760 mmHg

Density:0.916g/cm3

Index of Refraction:1.451

PSA:40.46000

Exact Mass:174.16200

LogP:1.80040

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD01631077 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD01631077 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD01631077 Use and application,MFCD01631077 technical grade,usp/ep/jp grade.

Related News: It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad. (3S,6S)-2,7-dimethyloctane-3,6-diol manufacturer Alira is betting big on biometrics services by picking up Italy-based CROS NT, which has offices in Italy, London and North Carolina. The deal, for undisclosed terms, gives a boost to Alira’s direct clinical operations in Europe and access to biometrics services from the 29-year-old contract research organization. (3S,6S)-2,7-dimethyloctane-3,6-diol supplier ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. (3S,6S)-2,7-dimethyloctane-3,6-diol vendor Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. (3S,6S)-2,7-dimethyloctane-3,6-diol factory ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety.